Study Stopped
no funding
Natural Cycle Versus Hormone Replaced Cycle
1 other identifier
interventional
N/A
0 countries
N/A
Brief Summary
Recent sutdies indicate that the existence of corpus lutein in the ovary is a key point to prevent preeclampsia, and patients undergoing FET with hormone replaced cycle have no corpus lutein and the absence of corpus lutein significantly increases the risk of preeclampsia in these patients. We aim to conduct a single center randomized controlled non-inferiority trial to compare the live birth rate and gestational hypertention disease rate between the natural cycle and the hormone replaced cycle in women undergoing FET.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Dec 2020
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 14, 2020
CompletedFirst Posted
Study publicly available on registry
March 17, 2020
CompletedStudy Start
First participant enrolled
December 10, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 10, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 10, 2020
CompletedAugust 24, 2026
August 1, 2026
Same day
March 14, 2020
August 20, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The Gestational hypertension rate
defined with blood pressure over 140/90 mmhg from gestational week 20 to delivery with or without other complications by the enrolled patients
delivery
Secondary Outcomes (1)
The pre-eclampsia rate
From gestational week 20 to delivery
Study Arms (2)
natural cycle for endometrium preparation
EXPERIMENTALpatients will not receive oral contraceptive drugs for menstruation or drugs for ovulation induction before embryo transfer and patients will ovulate before embryo transfer
hormone replaced cycle for endometrium preparation
ACTIVE COMPARATORpatients will receive oral contraceptive drugs for menstruation before embryo transfer and patients will not ovulate before embryo transfer
Interventions
patients will not use oral contraceptive drugs
patients will receive oral contraceptive drugs for menstruation before embryo transfer
Eligibility Criteria
You may qualify if:
- to 45 years old women;
- Scheduled to undergo frozen-thawed embryo transfer.
- Agreeing with the informed consent.
You may not qualify if:
- Hypertention disease before embryo transfer;
- Oocyte or sperm donated cycles
- Recurrent miscarriage (at least two miscarriage history)
- Ovulatory dysfunction
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Officials
- PRINCIPAL INVESTIGATOR
Dan Zhang, M.D. Ph.D.
Women's Hospital School Of Medicine Zhejiang University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 14, 2020
First Posted
March 17, 2020
Study Start
December 10, 2020
Primary Completion
December 10, 2020
Study Completion
December 10, 2020
Last Updated
August 24, 2026
Record last verified: 2026-08
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP
- Time Frame
- From January 2022 onwards
- Access Criteria
- Data will be shared on reasonable request
Data will be shared on reasonable request once the study has been complete